<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">avk</journal-id><journal-title-group><journal-title xml:lang="ru">Архивъ внутренней медицины</journal-title><trans-title-group xml:lang="en"><trans-title>The Russian Archives of Internal Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-6704</issn><issn pub-type="epub">2411-6564</issn><publisher><publisher-name>“SINAPS” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20514/2226-6704-2020-10-4-288-295</article-id><article-id custom-type="elpub" pub-id-type="custom">avk-1074</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Клинические особенности и инсулинорезистентность у мужчин с метаболически нездоровым фенотипом ожирения</article-title><trans-title-group xml:lang="en"><trans-title>Clinical Features and Insulin Resistance in Men with a Metabolically Unhealthy Obesity Phenotype</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панова</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Panova</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нижний Новгород</p></bio><bio xml:lang="en"><p>Nizhny Novgorod</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8280-2669</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пиманкина</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Pimankina</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нижний Новгород</p></bio><bio xml:lang="en"><p>Nizhny Novgorod</p></bio><email xlink:type="simple">marimed@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратаева</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Karataeva</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нижний Новгород</p></bio><bio xml:lang="en"><p>Nizhny Novgorod</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФКУЗ «Медико-санитарная часть МВД России по Нижегородской области»;   Кафедра эндокринологии и внутренних болезней ФГБОУ ВО «Приволжский исследовательский медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Hospital of «The health care of the Ministry of internal Affairs of Russia Nizhny Novgorod region»;  Department of Endocrinology and Internal Diseases of Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Кафедра эндокринологии и внутренних болезней ФГБОУ ВО «Приволжский исследовательский медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Endocrinology and Internal Diseases of Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>30</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>4</issue><fpage>288</fpage><lpage>295</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Панова Е.И., Пиманкина М.С., Каратаева О.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Панова Е.И., Пиманкина М.С., Каратаева О.В.</copyright-holder><copyright-holder xml:lang="en">Panova E.I., Pimankina M.S., Karataeva O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medarhive.ru/jour/article/view/1074">https://www.medarhive.ru/jour/article/view/1074</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: проанализировать особенности гормонально-метаболических показателей у больных с метаболически нездоровым фенотипом ожирения, выявить значение индекса TyG и индекса висцерального ожирения для диагностики инсулинорезистентности в дан ной группе больных.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: в исследование включено 108 мужчин трудоспособного возраста с индексом массы тела ≥25 кг/м2, госпитализированных в стационар. Все пациенты разделены на две группы: 1 — группа «метаболически здорового фенотипа», 2 — группа «метаболически нездорового фенотипа». Представлены результаты сравнительного одномоментного нерандомизированного описательного исследования двух групп пациентов. Использовались методы оценки антропометрических параметров, включающие расчёт индекса висцерального ожирения, процента жировой ткани в организме, а также лабораторные исследования общеклинического, биохимического и гормонального анализов крови. Детальная оценка инсулинорезистентности включала исследование индекса TyG. Применены статистические методы обработки данных, в том числе ROC-анализ.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение: в ходе исследования было установлено, что пациенты трудоспособного возраста с метаболически нездоровым фенотипом ожирения характеризуются неблагоприятными антропометрическими и гормонально-метаболическими показателями, а также более тяжелой полиморбидной патологией, главным образом кардиоваскулярной. Значения индекса висцерального ожирения, превышающие 2,5, сопровождаются снижением секреции антиатерогенного гормона адипонектина. Показатели индекса TyG более 3,98, индекс висцерального ожирения свыше 1,85 и объём жировой массы более 30,1% могут являться признаками инсулинорезистентности. Простота и доступность использования указанных показателей заключают в себе определённый экономический эффект.</p></sec><sec><title>Заключение</title><p>Заключение: исследование признаков инсулинорезистентности у больных с метаболически нездоровым фенотипом ожирения является важным аспектом обследования данной категории больных и целесообразно в практике первичного звена здравоохранения в силу доступности и простоты.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study: The aim of study was to analyze the characteristics of hormonal-metabolic parameters in men with a metabolically unhealthy obesity phenotype; identify the value of special indicators for diagnosis of insulin resistance.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: The examination included 108 patients with body mass index ≥25 kg/m2, which were hospitalized. According to the current national guidelines for the diagnosis and treatment of obesity, all examined patients were divided into 2 groups: 1 — with metabolically healthy obesity phenotype, 2 — with metabolically unhealthy obesity phenotype. The study presents the results of comparative simultaneous nonrandomized study of two groups with using of different methods of examination (anthropometric indicators, laboratory tests for inspection of the hormonal profile, biochemistry parameters, and calculation of TyG index for diagnosis of insulin resistance).</p></sec><sec><title>Results and discussion</title><p>Results and discussion: The study found that patients of working age with metabolically unhealthy obesity phenotype are characterized by unfavorable anthropometric and hormonal-metabolic parameters and more severe polymorbid pathology (first of all cardiovascular diseases). The results of study revealed the value of special indicators for the diagnosis of insulin resistance (visceral obesity index &gt;1,85; TyG &gt;3,98; fat mass &gt;30,1).</p></sec><sec><title>Conclusion</title><p>Conclusion: timely detection of insulin resistance indicators has great importance and practical application due to simplicity and accessibility. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>инсулинорезистентность</kwd><kwd>адипонектин</kwd><kwd>объем жировой массы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>insulin resistance</kwd><kwd>adiponectin</kwd><kwd>fat mass</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Романцова Т.И. Эпидемия ожирения: очевидные и вероятные причины. Ожирение и метаболизм. 2011; 1: 5-17.</mixed-citation><mixed-citation xml:lang="en">Romancova T.I. The obesity epidemic: obvious and probable causes. Obesity and metabolism. 2011; 1: 5-17. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lins L., Carvalho F.M. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016; 4: 2050312116671725. doi:10.1177/2050312116671725.</mixed-citation><mixed-citation xml:lang="en">Lins L., Carvalho F.M. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016; 4: 2050312116671725. doi:10.1177/2050312116671725.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Красильникова Е.И., Благосклонная Я.В., Быстрова А.А. и др. Адипозопатия — ключевое звено развития состояния инсулинорезистентности. Артериальная гипертензия. 2012; 18(2): 165-76. doi.org/10.18705/1607-419X-2012-18-2-164-176</mixed-citation><mixed-citation xml:lang="en">Krasil’nikova E.I., Blagosklonnaya YA.V., Bystrova A.A et al. Adiposopathy is a key element in the development of insulin resistance. Arterial Hypertension. 2012; 18(2): 165-76. doi. org/10.18705/1607-419X-2012-18-2-164-176 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Куршакова Л.Н., Шабанова Г.Ф., Шарифуллина Э.Р. и др. Инсулинорезистентность и нарушения углеводного обмена при метаболическом синдроме у мужчин. Казанский медицинский журнал. 2009; 90(2): 239-43.</mixed-citation><mixed-citation xml:lang="en">Kurshakova L.N., SHabanova G.F., SHarifullina E.R. et al. Insulin resistance and carbohydrate metabolism disorders in metabolic syndrome in males. Kazan medical journal. 2009; 90 (2): 239-43 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Beltrán-Sánchez H., Harhay M.O., Harhay M.M. et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol. 2013; 62(8): 697-703. doi: 10.1016/j. jacc.2013.05.064.</mixed-citation><mixed-citation xml:lang="en">Beltrán-Sánchez H., Harhay M.O., Harhay M.M. et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol. 2013; 62(8): 697-703. doi: 10.1016/j. jacc.2013.05.064.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kushner R.F., Kahan S. Introduction: The State of Obesity in 2017. Med Clin North Am. 2018; 102(1): 1-11. doi: 10.1016/j.mcna.2017.08.003.</mixed-citation><mixed-citation xml:lang="en">Kushner R.F., Kahan S. Introduction: The State of Obesity in 2017. Med Clin North Am. 2018; 102(1): 1-11. doi: 10.1016/j.mcna.2017.08.003.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Du T., Sun X., Yin P. et al. Secular trends in the prevalence of low risk factor burden for cardiovascular disease according to obesity status among Chinese adults, 1993–2009. BMC Public Health. 2014; 14: 961. doi: 10.1186/1471-2458-14-961.</mixed-citation><mixed-citation xml:lang="en">Du T., Sun X., Yin P. et al. Secular trends in the prevalence of low risk factor burden for cardiovascular disease according to obesity status among Chinese adults, 1993–2009. BMC Public Health. 2014; 14: 961. doi: 10.1186/1471-2458-14-961.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний. Национальные клинические рекомендации. Российское кардиологическое общество. Российское научное медицинское общество терапевтов. Антигипертензивная лига. Ассоциация клинических фармакологов. 2017: 3-164.</mixed-citation><mixed-citation xml:lang="en">Diagnosis, treatment, prevention of obesity and associated diseases. National clinical guidelines. Russian Cardiology Society. Russian Scientific Medical Society of Therapists. Antihypertensive League. Association of Clinical Pharmacologists. 2017: 3-164. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода С.В., Барыкина И.Н., Саласюк А.С. Национальные клинические рекомендации по ожирению: концепция и перспективы. Вестник ВолГМУ. 2017; 1(61): 134–9.</mixed-citation><mixed-citation xml:lang="en">Nedogoda S.V., Barykina I.N., Salasyuk A.S. National clinical recommendations for obesity: concept and prospects. Vestnik of Volgograd Medical University. 2017; 1(61): 134-9. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gallagher D., Heymsfield S.B., Heo M. et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. The American journal of clinical nutrition. 2000; 72(3): 694-701. doi: 10.1093/ajcn/72.3.694.</mixed-citation><mixed-citation xml:lang="en">Gallagher D., Heymsfield S.B., Heo M. et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. The American journal of clinical nutrition. 2000; 72(3): 694-701. doi: 10.1093/ajcn/72.3.694.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6): 1487-95. doi: 10.2337/ diacare.27.6.1487.</mixed-citation><mixed-citation xml:lang="en">Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6): 1487-95. doi: 10.2337/ diacare.27.6.1487.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J.W., Lim N.K., Park H.Y. The product of fasting plasma glucose and triglycerides improves risk prediction of type 2 diabetes in middle-aged Koreans. BMC Endocr Disord. 2018;18(1):33. doi: 10.1186/ s12902-018-0259-x.</mixed-citation><mixed-citation xml:lang="en">Lee J.W., Lim N.K., Park H.Y. The product of fasting plasma glucose and triglycerides improves risk prediction of type 2 diabetes in middle-aged Koreans. BMC Endocr Disord. 2018;18(1):33. doi: 10.1186/ s12902-018-0259-x.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Letters. 2006; 580(12): 2917-21. doi: 10.1016/j.febslet.2006.04.028.</mixed-citation><mixed-citation xml:lang="en">Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Letters. 2006; 580(12): 2917-21. doi: 10.1016/j.febslet.2006.04.028.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Maeda N., Shimomura I., Kishida K. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002; 8(7): 731-7. doi: 10.1038/nm724.</mixed-citation><mixed-citation xml:lang="en">Maeda N., Shimomura I., Kishida K. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002; 8(7): 731-7. doi: 10.1038/nm724.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Anari R., Amani R., Latifi S.M. et al. Association of obesity with hypertension and dyslipidemia in type 2 diabetes mellitus subjects. Diabetes Metab Syndr Clin Res Rev. 2017; 11(1): 37-41. doi: 10.1016/j. dsx.2016.07.004.</mixed-citation><mixed-citation xml:lang="en">Anari R., Amani R., Latifi S.M. et al. Association of obesity with hypertension and dyslipidemia in type 2 diabetes mellitus subjects. Diabetes Metab Syndr Clin Res Rev. 2017; 11(1): 37-41. doi: 10.1016/j. dsx.2016.07.004.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Adamska A., Nikolajuk A., Karczewska-Kupczewska M. et al. Relationships between serum adiponectin and soluble TNF-a receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol. 2012; 49(1): 17-24. doi: 10.1007/s00592-010-0252-y</mixed-citation><mixed-citation xml:lang="en">Adamska A., Nikolajuk A., Karczewska-Kupczewska M. et al. Relationships between serum adiponectin and soluble TNF-a receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol. 2012; 49(1): 17-24. doi: 10.1007/s00592-010-0252-y</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Amato M.C., Giordano C., Pitrone M. et al. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011; 10: 183. doi:10.1186/1476-511X-10-183.</mixed-citation><mixed-citation xml:lang="en">Amato M.C., Giordano C., Pitrone M. et al. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011; 10: 183. doi:10.1186/1476-511X-10-183.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammadreza B., Farzad H., Davoud K. et al. Prognostic significance of the complex «Visceral Adiposity Index» vs. simple anthropometric measures: Tehran lipid and glucose study. Cardiovasc Diabetol. 2012; 11: 20. doi:10.1186/1475-2840-11-20.</mixed-citation><mixed-citation xml:lang="en">Mohammadreza B., Farzad H., Davoud K. et al. Prognostic significance of the complex «Visceral Adiposity Index» vs. simple anthropometric measures: Tehran lipid and glucose study. Cardiovasc Diabetol. 2012; 11: 20. doi:10.1186/1475-2840-11-20.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
